<Disease><Name>REFSUM DISEASE, CLASSIC</Name><Synonym>PHYTANIC ACID OXIDASE DEFICIENCY; PHYTANIC ACID STORAGE DISEASE</Synonym><OMIM><Number>266500</Number><URL>http://omim.org/entry/266500</URL></OMIM><Orphanet><Number>773</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=773</URL></Orphanet><Protein><Number>phytanoyl-CoA dioxygenase, peroxisomal</Number><URL>http://www.uniprot.org/uniprot/O14832</URL></Protein><ExPASy><Number>1.14.11.18</Number><URL>http://enzyme.expasy.org/EC/1.14.11.18</URL></ExPASy><Gene>10p13</Gene><ICD>G60.1</ICD><Summary>rare (&gt;200 cases) ;autosomal recessive ;mutation in the gene encoding phytanoyl-CoA hydroxylase;two genes, PHYH/PAHX (45%) and PEX7, have been identified to cause Refsum disease</Summary><Symptoms><symtomp><id>2209</id><symptom>anosmia</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3158</id><symptom>cardiac involvement, defects or anomalies</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>1877</id><symptom>cardiomegaly</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2104</id><symptom>cardiomyopathy</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>1736</id><symptom>cataract</symptom><category>EYES</category></symtomp><symtomp><id>2227</id><symptom>dysmorphism / dysmorphic features</symptom><category>HEAD</category></symtomp><symtomp><id>1883</id><symptom>ECG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2433</id><symptom>hearing defect, deafness</symptom><category>EARS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1878</id><symptom>heart failure, cardiac failure</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2214</id><symptom>hyporeflexia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2114</id><symptom>ichthyosis</symptom><category>SKIN</category></symtomp><symtomp><id>3357</id><symptom>muscle atrophy / muscular atrophy</symptom><category>MUSCLES</category></symtomp><symtomp><id>1787</id><symptom>muscle weakness</symptom><category>MUSCLES</category></symtomp><symtomp><id>1917</id><symptom>neurological deterioration / neurologic deterioration</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>3369</id><symptom>neuropathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2349</id><symptom>night blindness / nyctalopia</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1723</id><symptom>nystagmus</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1915</id><symptom>onset, adulthood / adoulthood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>4016</id><symptom>paresis</symptom><category>MUSCLES</category></symtomp><symtomp><id>1939</id><symptom>peripheral neuropathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1731</id><symptom>retinitis pigmentosa</symptom><category>EYES</category></symtomp><symtomp><id>4017</id><symptom>sensory disturbances</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2342</id><symptom>skeletal changes, skeletal abnormalities</symptom><category>SKELATAL DEFECT | SKELETAL DEFECT</category></symtomp><symtomp><id>4018</id><symptom>spinal muscular atrophy</symptom><category>MUSCLES</category></symtomp></Symptoms><Metabolites><metabolite><id>840</id><name>Phytanic acid oxidation</name><specimen>fibroblasts</specimen><value>decreased</value><min>5.30</min><max>18.80</max><unit>% oxidized</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>436</id><name>Phytanic acid</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>3.10</max><unit>&#956;g/ml</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>500</id><name>Phytanic acid</name><specimen>plasma</specimen><value>increased</value><min>0.00</min><max>4.00</max><unit>&#956;g/ml</unit><age>child</age><method /><comment /></metabolite><metabolite><id>881</id><name>Phytanic acid</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.00</min><max>4.00</max><unit>&#956;g/l</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>766</id><name>Protein, total</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>10.00</min><max>30.00</max><unit>mg/dl</unit><age>child</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>4931</id><title>Refsum Disease</title><author>Wanders RJA,</author><journal>GeneReviews&#174; [Internet]</journal><year>2015</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Waterham HR, Leroy BP</co_aut></literature><literature><id>4932</id><title>Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy</title><author>Rueether K,</author><journal>Surv Ophthalmol</journal><year>2010</year><book /><volume>55</volume><number>6</number><pages>531-538</pages><co_aut>et al.</co_aut></literature><literature><id>2079</id><title>Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7)</title><author>Jansen GA</author><journal>Hum Mutat</journal><year>2004</year><book /><volume>23</volume><number>3</number><pages>209-218</pages><co_aut>et al.</co_aut></literature><literature><id>2080</id><title>Further studies on the substrate spectrum of phytanoyl-CoA hydroxylase: implications for Refsum disease?</title><author>Foulon V</author><journal>J Lipid Res</journal><year>2003</year><book /><volume>44</volume><number>12</number><pages>2349-2355</pages><co_aut>et al.</co_aut></literature><literature><id>2081</id><title>Phytanic acid alpha-oxidation, new insights into an old problem: a review</title><author>Wanders RJ</author><journal>Biochim Biophys Acta</journal><year>2003</year><book /><volume>1631</volume><number>2</number><pages>119-135</pages><co_aut>Jansen GA, Lloyd MD</co_aut></literature><literature><id>2083</id><title>Phytanic acid storage disease (Refsums disease): clinical characteristics, pathophysiology and the role of therapeutic apheresi</title><author>Weinstein R</author><journal>J Clin Apheresis</journal><year>1999</year><book /><volume>14</volume><number>4</number><pages>181-184</pages><co_aut /></literature><literature><id>2077</id><title>Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene</title><author>Jansen GA</author><journal>Nat Genet</journal><year>1997</year><book /><volume>17</volume><number>2</number><pages>190-193</pages><co_aut>et al.</co_aut></literature><literature><id>118</id><title>Refsum disease</title><author>Steinberg D</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>0</number><pages>2351-2369</pages><co_aut /></literature><literature><id>229</id><title>Peroxisomal disorders</title><author>Heymans HS</author><journal>J Inherit Metab Dis</journal><year>1995</year><book /><volume>0</volume><number>0</number><pages>421-433</pages><co_aut>Wanders RJA, Schutgens RBH</co_aut></literature><literature><id>236</id><title>Measurement of phytanic acid levels</title><author>Moser HW</author><journal>Techniques in diagnostic human biochemical genetics: a laboratory manual; Editor F.A.Hommes;Wiley-Liss Inc. New York</journal><year>1991</year><book /><volume>0</volume><number>0</number><pages>193-203</pages><co_aut>Moser AB</co_aut></literature><literature><id>1186</id><title>[Refsums disease. Apropos of 2 cases disclosed by myocardiopathy.]</title><author>Millaire A</author><journal>Ann Cardiol Angeiol</journal><year>1990</year><book /><volume>39</volume><number>0</number><pages>173-178</pages><co_aut>et al.</co_aut></literature><literature><id>235</id><title>The significance of plasma phytanic acid levels in adults</title><author>Britton TC</author><journal>J Neurol Neurosurg Psychiatry</journal><year>1989</year><book /><volume>52</volume><number>0</number><pages>891</pages><co_aut>et al.</co_aut></literature><literature><id>2084</id><title>A child with Refsums disease: successful treatment with diet and plasma exchange</title><author>Dickson N</author><journal>Dev Med Child Neurol</journal><year>1989</year><book /><volume>31</volume><number>1</number><pages>92-97</pages><co_aut>et al.</co_aut></literature><literature><id>237</id><title>Clinical and biochemical hetrogeneity in conditions with phytanic acid accumulation</title><author>Skjeldal OH</author><journal>J Neurol Sci</journal><year>1987</year><book /><volume>77</volume><number>0</number><pages>87-96</pages><co_aut>Stokke O</co_aut></literature></Literatures></Disease>